Company intelligence / Profile preview
Biscayne Pharmaceuticals
Miami, Florida, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Biscayne Pharmaceuticals focused on the development of GHRH analogs for cancer and cardiac indications and sponsored clinical-stage assets for CNS diseases, including BIS-001 (synthetic huperzine A) for epilepsy, which demonstrated safety and efficacy in Phase 1. Its principal epilepsy asset was spun out as Biscayne Neurotherapeutics and later acquired by Supernus Pharmaceuticals.[1][2][6]
- Therapeutic areas
- OncologyNeurologyCardiovascular
- Modalities
- Small moleculeAcetylcholinesterase inhibitorBiologic (GHRH agonist/antagonist)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Biscayne Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biscayne Pharmaceuticals.